tbuckley/cabot-search huggingface dataset:
Home Nursing. Modern Scientific Methods for the Care of the Sick.
Authors: Eveleen Harrison
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.
Authors: Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher
Journal: Blood (2009)
EXTRA-UTERINE PREGNANCY.
Authors: Edward Armin Schumann
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 342: Developing an In Vivo Model of Ventricular Refibrillation
Authors: Nima Zamiri, Andrew Ramadeen, Xudong Hu, Talha Farid, Stephane Masse, Paul Dorian, Kumaraswamy Nanthakumar
Journal: Circulation (2012)

Background Ventricular refibrillation, defined as re-emergence of VF following successful defibrillation, is as frequent as 79% after out of hospital cardiac arrest, with at least 50% of patients experiencing more than 1 episode of refibrillation. Re-fibrillations are harder to defibrillate and are inversely associated with survival. The mechanism of refibrillation is not known. In order to test hypotheses on preventing or treating refibrillation, a reliable in-vivo refibrillation model is necessary. Pigs have been used as a reliable model to study the efficacy of CPR. Here we present a swine model of ventricular refibrillation following VF. Methods &amp; Results Twenty-four Yorkshire pigs were anesthetized. Three Millar catheters were used to measure pressure from abdominal Aorta, RA and LV. An EP catheter was introduced in the RV to induce VF. VF was induced by burst pacing and left untreated for 4 minutes. Then chest compressions were delivered using a pneumatic device at a constant rate of 120/min and manual ventilation was delivered at 6 breaths/min. All animals were defibrillated after 3 min of CPR at 150J, and increasing energy in case of failure. After successful defibrillation, they were observed for a period of 30 min for any occurrence of refibrillation. Refibrillations were treated with defibrillation. The initial VF could not be defibrillated in 3 (12%). Refibrillation occurred in 13 (62%). The mean time to onset of refibrillation was 629 sec after successful defibrillation ranging from 8 to 1600 sec. Mean number of re-fibrillations was 1.14±1.15 (max: 4) with 33.33% (n=7) experiencing more than one episode of refibrillation. Forty-six percent of refibrillations occurred within first 5 min after defibrillation. Overall Survival was 37.5% (n=9). Survival was 38% in re-fibrillation group vs. 44.4% in non-refibrillation group (p=nsS). With regards to initiation, 60% of episodes were preceded by 1 PVC and 20% were preceded by 2 PVCs or more. Conclusion We have developed a swine model of ventricular re-fibrillation that resembles reported human data in terms of incidence of re-fibrillation and initiation following VF arrest. This model will serve as a test bed for different pharmacologic and interventional strategies focused on modulating refibrillation.
Initial management of a major burn: I—overview
Authors: Shehan Hettiaratchy, Remo Papini
Journal: BMJ (2004)

A major burn is defined as a burn covering 25% or more of total body surface area, but any injury over more than 10% should be treated similarly.Rapid assessment is vital.The general approach to a major burn can be extrapolated to managing any burn.The most important points are to take an accurate history and make a detailed examination of the patient and the burn, to ensure that key information is not missed.This article outlines the structure of the initial assessment.The next article will cover the detailed assessment of burn surface area and depth and how to calculate the fluid resuscitation formula. History takingThe history of a burn injury can give valuable information about the nature and extent of the burn, the likelihood of inhalational injury, the depth of burn, and probability of other injuries.The exact mechanism of injury and any prehospital treatment must be established.A patient's history must be obtained on admission, as this may be the only time that a first hand history is obtainable.Swelling may develop around the airway in the hours after injury and require intubation, making it impossible for the patient to give a verbal history.A brief medical history should be taken, outlining previous medical problems, medications, allergies, and vaccinations.Patients' smoking habits should be determined as these may affect blood gas analyses.
CONSTITUTIONAL REACTIONS FROM BACTERIAL VACCINES
Authors: Boen Swinny
Journal: Annals of Internal Medicine (1940)

Case Reports1 September 1940CONSTITUTIONAL REACTIONS FROM BACTERIAL VACCINESBOEN SWINNY, M.D.BOEN SWINNY, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-14-3-521 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe recent communication of Brown1 indicates that constitutional reactions from bacterial vaccines never resemble those occurring from injections of protein extracts. Herewith is reported an exception, the only one I have observed in 240 asthmatics treated with bacterial vaccines.CASE REPORTE. J. D., male, aged 12, with a history of winter asthma of bacterial origin since the age of three, and under my care since the age of six, in the fall of 1937 gave a very strong immediate whealing reaction from the intradermal injection of 0.02 c.c. of Squibb's Catarrhal Vaccine No. 5. A moderately strong direct reaction...Bibliography1. BROWN GT: Constitutional reactions from bacterial vaccines, ANN. INT. MED., 1938, xii, 493. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: San Antonio, Texas*Received for publication June 13, 1939. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1940Volume 14, Issue 3Page: 521-522KeywordsAsthmaFallsIntradermal injectionsProteinsVaccines ePublished: 1 December 2008 Issue Published: 1 September 1940 PDF downloadLoading ...
Introduction of computerized provider order entry (CPOE) and time impact in an inpatient hematology/oncology service: Serial time and motion studies
Authors: D. A. Hanauer, R. W. Beasley, J. Schumacher, M. G. Duck, D. W. Blayney
Journal: Journal of Clinical Oncology (2009)

e17507 Background: The impact of CPOE on inpatient hematology/oncology care is not well studied. CPOE has many benefits, but concerns exist about increased time required to enter electronic orders compared to handwritten orders. We hypothesized that CPOE would require more order-related time from caregivers, and reduce the amount of time for direct patient care. Methods: Physician assistants (PAs) enter all patient orders (except those for chemotherapy) and are the dedicated and exclusive care providers on this non-house staff service at the main Hospital of the University of Michigan Health System. We chose the PA service for observation as we could eliminate potential biases introduced by rotating house staff we observed in earlier studies. PAs were directly observed at -1, +3 and +8 months post implementation of a CPOE system (Sunrise Clinical Manager, Eclypsis, Atlanta GA). Dedicated observers used a data entry tool with a modified database (available on the Health IT Tools section at healthit.ahrq.gov) on a tablet computer. For analysis, the 60 individual activities were grouped into 6 major categories, as well as an ordering category. We observed the same three PAs for 82.5 hours pre-CPOE, for 75.0 hours at 3 months post and for 70.5 hours 8 months post. Productive time was all non-personal and non-administrative time. The faculty entered chemotherapy orders and supervised the PAs, but were not studied. Results: Overall time for order-related activities was unchanged during the three observation periods, requiring 10.3, 10.6 and 11.4% of productive time, respectively. Time spent on direct patient care (as a percentage of productive time) was also unchanged once CPOE was implemented (50.7% pre vs. 49.8% and 47.8% post). Conclusions: We could not detect differences in order-entry time by well-trained PAs using standardized order sets before and after CPOE implementation on an inpatient hematology/oncology service. The decision to adopt CPOE should not be based on the hypothesis that there will be less (or more) time spent on order entry tasks. No significant financial relationships to disclose.
Abstract 9639: Pre-Transplant Circulating Antibodies Predict Development of Antibody-Mediated Rejection after Heart Transplant Using the New ISHLT Antibody-Mediated Rejection Pathology Grading Scale
Authors: Michelle Kittleson, Jignesh Patel, Matthew Rafiei, Antoine Hage, Lily Stern, Fardad Esmailian, Nancy Reinsmoen, Jon Kobashigawa
Journal: Circulation (2012)

Purpose: Pre-transplant circulating antibodies have been associated with the development of antibody mediated rejection (AMR) following heart transplantation. The new pathology antibody mediated rejection scale was developed in 2009 and now the diagnosis of antibody mediated rejection is standardized through this pathology scale. We chose to assess whether pre-transplant circulating antibodies do indeed lead to more pathology antibody mediated rejection according to the new International Society for Heart and Lung Transplantation (ISHLT) AMR grading scale. Methods: Between January 1, 2010 and July 1, 2011 we evaluated 106 heart transplant recipients for their pre-transplant percentages of peak panel reactive antibody (PRA). Patients were divided into the following subgroups depending on the percentage of peak pre-transplant PRA: peak PRA 0-9% (n = 67), PRA ≥ 10% (n = 39), PRA ≥ 25% (n = 31), PRA ≥ 50% (n = 25), PRA ≥ 75% (n = 19), and PRA = 100% (n = 4). The endpoints of this study were first-year pathology antibody mediated rejection and treated antibody mediated rejection. Treated antibody mediated rejection was mainly due to symptoms of heart failure and or decrease in left ventricular ejection fraction. Results: Patients with higher pre-transplant PRA's had significantly more pathology antibody mediated rejection in the first-year after heart transplantation compared to patients with a peak PRA 0-9% (see table). The number of treated antibody mediated rejection episodes also increased with higher PRA's, which were also significantly different from the peak PRA 0-9% group. Conclusion: Pre-transplant circulating antibodies appear to predict pathology antibody mediated rejection according to the most recent ISHLT grading scale. This appears to confirm that pre-transplant circulating antibodies greater than 10% is a threshold for antibody-mediated rejection and therefore consideration for augmentation of immunosuppression should be considered.
The Medical Museum: Modern Developments, Organisation and Technical Methods Based on a New System of Visual Teaching.
Authors: S. H. Daukes
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hypertension and the Kidney
Authors: Christopher S. Wilcox
Journal: BMJ (1959)

The kidney in blood pressure regulation Renal parenchymal disease and hypertension Renovascular hypertension and ischemic nephropathy Adrenal causes of hypertension Insulin resistance and hypertension The role of hypertension in progression of chronic renal disease Pharmacologic treatment of hypertension Hypertensive crises. Index.
Thrombolysis in patients with diabetes
Authors: D K Newman, M P Snead, D W Flanagan, J D Scott
Journal: BMJ (1995)

We are particularly concerned that the box giving clinical implications states that "computed tomography is recommended as part of the diag- nostic investigation for adults with a first generalised seizure."Approximately 4-7% of men and 3-7% of women in the whole population will have at least one epileptic seizure during their life,' and we need cost effective policies.The decision whether scanning should be performed depends, as always, on a careful history (which will include the possible role of alcohol, as discussed by Schoenberger and Heim) and physical examina- tion.We believe that previously suggested practice remains valid: people who have had a first seizure should be scanned if the clinical onset of the seizure was clearly partial or if there are focal neurological signs that are not clearly accounted for by known pre-existing neurological damage such as cerebral palsy or embolus.4
A Further Study of Dental Clinics in the United States.
Authors: Miriam Simons Leuck, Charles Annsson Randlett Wardwell
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 11819: Follistatin-like 1, a Muscle-derived Secreted Protein, Reduces Neointimal Hyperplasia and Modulates Smooth Muscle Cell Function
Authors: Megumi Miyabe, Koji Ohashi, Rei Shibata, Yusuke Uemura, Yasuhiro Ogura, Daisuke Yuasa, Takahiro Kambara, Yoshiyuki Kataoka, Kazuhiro Matsuo, Takashi Enomoto, Kenneth Walsh, Toyoaki Murohara, Noriyuki Ouchi
Journal: Circulation (2012)

Background: Pathological vascular remodeling is one of crucial steps of various cardiovascular diseases including restenosis after coronary intervention. Smooth muscle cell (SMC) proliferation and migration are key features during vascular remodeling. We have shown that follistatin-like 1 (Fstl1) acts as a muscle-derived secretory factor that exerts beneficial actions on cardiac damage and endothelial function. However, nothing is known about the role of Fstl1 in regulating pathological vascular remodeling. Here, we investigated the effect of Fstl1 on neointimal formation and smooth muscle cell function. Methods and results: Skeletal muscle-specific Fstl1 transgenic (Tg) mice and wild type (WT) mice were subjected to vascular wire injury. Fstl1-Tg mice showed attenuated neointimal thickenings at 3 weeks after vascular injury compared with WT mice, which was accompanied with decreased proliferative BrdU-positive cells in the neointima. In cultured human aortic SMC (HASMC), treatment with recombinant human ...
Abstract 1744: Adenylate-Cyclase VI Transforms Ventricular Cardiomyocytes Into Biological Pacemaker Cells
Authors: Arjang Ruhparwar, Klaus Kallenbach, Gunnar Klein, Mahyar E Makoui, Christoph Bara, Daniel C Sigg, Axel Haverich, Matthias Karck, Michael Niehaus
Journal: Circulation (2007)

Background- Genetic therapy of arrhythmic disorders of the heart has been subject of extensive studies. Cyclic AMP (cAMP) is generated in response to β-adrenergic receptor stimulation and also binds to HCN channels, where it regulates spontaneous rhythmic activity in the heart. Aim of this study was to demonstrate whether in-vivo adenoviral gene transfer of Adenylate-Cyclase type VI (AC VI ) can create biological pacemaker activity in a porcine atrioventricular node (AV-node) block model. Methods and Results- Adenovirus encoding either AC VI or β-Galactosidase (lacZ) gene were injected into the lateral wall of the left ventricle of adult pigs via anterolateral thoracotomy at a dose of 10 10 virus particles each. After 12 days, the AV-node was ablated and three-dimensional electrophysiological cardiac mapping was performed using the Ensite™ electro-anatomical system. After rapid ventricular pacing and administration of Isoprenalin all animals of the AC-VI group exhibited an escape rhythm originating from the area of the left ventricular injection site at a rate of 100 ± 7 beats/minute (n = 5), while the escape rhythms in the control group (n = 4) originated from the right ventricle. Western blot analysis of the injection sites revealed a significantly higher expression of AC-VI in the respective group as compared to the control group. Conclusions- Our study demonstrates that AC-VI gene transfer may be a novel method to create a biological pacemaker
Scotin expression and survival in breast cancer
Authors: J. Bourdon, A. Diot, B. Vojtesek, S. Bray, L. Jordan, D. P. Lane, A. Thompson
Journal: Journal of Clinical Oncology (2009)

e22006 Background: The Scotin gene (3p21.3) is directly trans-activated by p53 in response to ionising radiation and produces a 25kD trans-membrane protein located in the endoplasmic reticulum and nuclear membrane which induces a caspase- dependent apoptosis. This study examines the expression of scotin and scotin isoforms in breast cancer in relation to clinical and pathological parameters. Methods: Scotin was examined in 145 breast cancers by DNA sequencing, nested PCR for mRNA expression and using novel antibodies to scotin (pantropic), the C-terminal or N-terminal domain, and the scotin-5 isoform with western blotting and immunohistochemistry on a tissue microarray of breast cancers. Results: Scotin was mutated in 10% of cancers and mRNA expression lost in a further 10%. Moreover, Scotin-5 was expressed in 40% of cancers, while it was not detectable in normal breast epithelium. We established that Scotin-5 is anti-apoptotic and inhibits scotin-mediated apoptosis. Cytoplasmic staining of scotin on TMAs demonstrated that loss of scotin expression was associated with earlier relapse (Mantel-Cox log rank p&lt;0.01) and poor survival (Mantel-Cox log rank p&lt;0.002). Furthermore, loss of Scotin expression identified 50% of the WTp53 patients or 50% of the ER+ patients who also had a poor survival. Conclusions: Scotin may be used as an independent biomarker in breast cancer. Loss of Scotin function may account for a significant proportion of p53 malfunction even in the presence of wild type p53 in breast cancer and adds a further level of complexity to p53 directed therapy in breast cancer. No significant financial relationships to disclose.